Skip to search formSkip to main contentSkip to account menu

saroglitazar

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH… 
Review
2019
Review
2019
BackgroundSaroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an… 
Review
2019
Highly Cited
2018
Highly Cited
2018
Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions… 
Review
2016
Review
2016
Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD), the absence of approved therapies is… 
Review
2015
Review
2015
  • S. Joshi
  • Expert opinion on pharmacotherapy
  • 2015
  • Corpus ID: 207480895
Introduction: Diabetes and dyslipidemia are commonly associated modifiable risk factors for cardiovascular diseases. Majority of… 
Highly Cited
2015
Highly Cited
2015
Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and… 
Highly Cited
2014
Highly Cited
2014
BACKGROUND Dyslipidemia due to diabetes is characterized by hypertriglyceridemia and reduced levels of high-density lipoprotein… 
Highly Cited
2014
Highly Cited
2014
Background: Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPAR… 
Highly Cited
2014
Highly Cited
2014
  • R. Agrawal
  • Current drug targets
  • 2014
  • Corpus ID: 20165940
The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the…